DATE: August 27, 2020
TIME: 7:00am PT, 10am ET
Novel anti-viral medications, including biologics and small molecule inhibitors, as well as serologic diagnostic tool sets are in urgent demand to fight the COVID-19 pandemic. As the initial point of drug discovery, it is crucial to obtain high-quality virus proteins as starting materials for immunization and lead compound screenings. SARS-CoV-2 is comprised of a genome that yields ~25 proteins with various functionalities.
This presentation focuses on our current progress of using recombinant protein expression technology to construct a protein library containing important SARS-CoV-2 structural proteins and their mutants as well as a collection of virus enzymes to facilitate drug screening campaigns. An array of spike protein mutants were expressed in eukaryote cell cultures and validated for ACE2 interactions to facilitate antibody screening and validations. Meanwhile, several optimization and engineering methods were applied to produce high quality nucleocapsid protein with correct self-assembly patterns and key SARS-CoV-2 enzymes with confirmed activities. Lastly, we introduce the continuous work-flow of a HEK293-based high-throughput antibody/protein expression platform as a powerful basis for antibody/protein library generation.
- The importance of virus proteins in anti-viral drug discoveries and serologic assay tool developments
- Development of recombinant SARS-CoV-2 protein library
- Describe optimization and engineering methods for high-quality virus protein production
- Discuss SARS-CoV-2 spike protein mutations
- Introduce the high-throughput “ViteMab” recombinant antibody/protein platform
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.